82 related articles for article (PubMed ID: 22300821)
1. Value of subtraction MRI in assessing treatment response following image-guided loco-regional therapies for hepatocellular carcinoma.
Winters SD; Jackson S; Armstrong GA; Birchall IW; Lee KH; Low G
Clin Radiol; 2012 Jul; 67(7):649-55. PubMed ID: 22300821
[TBL] [Abstract][Full Text] [Related]
2. Hepatocellular carcinoma: assessment of response to transarterial chemoembolization with image subtraction.
Kim S; Mannelli L; Hajdu CH; Babb JS; Clark TW; Hecht EM; Taouli B
J Magn Reson Imaging; 2010 Feb; 31(2):348-55. PubMed ID: 20099348
[TBL] [Abstract][Full Text] [Related]
3. Can the patient with cirrhosis be imaged for hepatocellular carcinoma without gadolinium?: Comparison of combined T2-weighted, T2*-weighted, and diffusion-weighted MRI with gadolinium-enhanced MRI using liver explantation standard.
Hardie AD; Kizziah MK; Rissing MS
J Comput Assist Tomogr; 2011; 35(6):711-5. PubMed ID: 22082541
[TBL] [Abstract][Full Text] [Related]
4. Assessment of tumor necrosis of hepatocellular carcinoma after chemoembolization: diffusion-weighted and contrast-enhanced MRI with histopathologic correlation of the explanted liver.
Mannelli L; Kim S; Hajdu CH; Babb JS; Clark TW; Taouli B
AJR Am J Roentgenol; 2009 Oct; 193(4):1044-52. PubMed ID: 19770328
[TBL] [Abstract][Full Text] [Related]
5. Hypervascular hepatocellular carcinoma in the cirrhotic liver: diffusion-weighted imaging versus superparamagnetic iron oxide-enhanced MRI.
Chung J; Yu JS; Kim DJ; Chung JJ; Kim JH; Kim KW
Magn Reson Imaging; 2011 Nov; 29(9):1235-43. PubMed ID: 21907517
[TBL] [Abstract][Full Text] [Related]
6. Contribution of diffusion-weighted magnetic resonance imaging in the characterization of hepatocellular carcinomas and dysplastic nodules in cirrhotic liver.
Xu PJ; Yan FH; Wang JH; Shan Y; Ji Y; Chen CZ
J Comput Assist Tomogr; 2010 Jul; 34(4):506-12. PubMed ID: 20657216
[TBL] [Abstract][Full Text] [Related]
7. Additional value of gadoxetic acid-DTPA-enhanced hepatobiliary phase MR imaging in the diagnosis of early-stage hepatocellular carcinoma: comparison with dynamic triple-phase multidetector CT imaging.
Haradome H; Grazioli L; Tinti R; Morone M; Motosugi U; Sano K; Ichikawa T; Kwee TC; Colagrande S
J Magn Reson Imaging; 2011 Jul; 34(1):69-78. PubMed ID: 21598343
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of HCC response to locoregional therapy: Validation of MRI-based response criteria versus explant pathology.
Gordic S; Corcuera-Solano I; Stueck A; Besa C; Argiriadi P; Guniganti P; King M; Kihira S; Babb J; Thung S; Taouli B
J Hepatol; 2017 Dec; 67(6):1213-1221. PubMed ID: 28823713
[TBL] [Abstract][Full Text] [Related]
9. Detection of hepatocellular carcinoma (HCC) using super paramagnetic iron oxide (SPIO)-enhanced MRI: Added value of diffusion-weighted imaging (DWI).
Nishie A; Tajima T; Ishigami K; Ushijima Y; Okamoto D; Hirakawa M; Nishihara Y; Taketomi A; Hatakenaka M; Irie H; Yoshimitsu K; Honda H
J Magn Reson Imaging; 2010 Feb; 31(2):373-82. PubMed ID: 20099351
[TBL] [Abstract][Full Text] [Related]
10. Hepatocellular carcinoma in patients with chronic liver disease: a comparison of gadoxetic acid-enhanced MRI and multiphasic MDCT.
Baek CK; Choi JY; Kim KA; Park MS; Lim JS; Chung YE; Kim MJ; Kim KW
Clin Radiol; 2012 Feb; 67(2):148-56. PubMed ID: 21920517
[TBL] [Abstract][Full Text] [Related]
11. Added value of breathhold diffusion-weighted MRI in detection of small hepatocellular carcinoma lesions compared with dynamic contrast-enhanced MRI alone using receiver operating characteristic curve analysis.
Xu PJ; Yan FH; Wang JH; Lin J; Ji Y
J Magn Reson Imaging; 2009 Feb; 29(2):341-9. PubMed ID: 19161186
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of image registration in subtracted 3D dynamic contrast-enhanced MRI of treated hepatocellular carcinoma.
Sundarakumar DK; Wilson GJ; Osman SF; Zaidi SF; Maki JH
AJR Am J Roentgenol; 2015 Feb; 204(2):287-96. PubMed ID: 25615750
[TBL] [Abstract][Full Text] [Related]
13. Gadoxetic acid-enhanced magnetic resonance imaging for differentiating small hepatocellular carcinomas (< or =2 cm in diameter) from arterial enhancing pseudolesions: special emphasis on hepatobiliary phase imaging.
Sun HY; Lee JM; Shin CI; Lee DH; Moon SK; Kim KW; Han JK; Choi BI
Invest Radiol; 2010 Feb; 45(2):96-103. PubMed ID: 20057319
[TBL] [Abstract][Full Text] [Related]
14. Gadoxetate disodium-enhanced magnetic resonance imaging versus contrast-enhanced 18F-fluorodeoxyglucose positron emission tomography/computed tomography for the detection of colorectal liver metastases.
Seo HJ; Kim MJ; Lee JD; Chung WS; Kim YE
Invest Radiol; 2011 Sep; 46(9):548-55. PubMed ID: 21577131
[TBL] [Abstract][Full Text] [Related]
15. Local tumour progression after loco-regional therapy of hepatocellular carcinomas: value of fusion imaging-guided radiofrequency ablation.
Min JH; Lee MW; Rhim H; Cha DI; Lim S; Choi SY; Lim HK
Clin Radiol; 2014 Mar; 69(3):286-93. PubMed ID: 24332169
[TBL] [Abstract][Full Text] [Related]
16. The role of functional MR imaging in the assessment of tumor response after chemoembolization in patients with hepatocellular carcinoma.
Kamel IR; Bluemke DA; Eng J; Liapi E; Messersmith W; Reyes DK; Geschwind JF
J Vasc Interv Radiol; 2006 Mar; 17(3):505-12. PubMed ID: 16567675
[TBL] [Abstract][Full Text] [Related]
17. [Role of magnetic resonance in the follow-up o hepatocarcinoma treated with percutaneous ethanol injection (PEI) or transarterial chemoembolization (TACE)].
De Cobelli F; Castrucci M; Sironi S; Livraghi T; Venturini M; Salvioni M; Del Maschio A
Radiol Med; 1994 Dec; 88(6):806-17. PubMed ID: 7878241
[TBL] [Abstract][Full Text] [Related]
18. Additional diffusion-weighted imaging in the detection of new, very small hepatocellular carcinoma lesions after interventional therapy compared with conventional 3 T MRI alone.
Qu JR; Li HL; Shao NN; Li X; Yan GL; Zhang HK; Luo JP; Zhang SN; Li YL; Liu CC
Clin Radiol; 2012 Jul; 67(7):669-74. PubMed ID: 22336669
[TBL] [Abstract][Full Text] [Related]
19. Assessment of ablative margin by unenhanced magnetic resonance imaging after radiofrequency ablation for hepatocellular carcinoma.
Koda M; Tokunaga S; Miyoshi K; Kishina M; Fujise Y; Kato J; Matono T; Okamoto K; Murawaki Y; Kakite S
Eur J Radiol; 2012 Oct; 81(10):2730-6. PubMed ID: 22137612
[TBL] [Abstract][Full Text] [Related]
20. [Hepatic and hepatocarcinoma magnetic resonance: comparison of the results obtained with paramagnetic (gadolinium) and superparamagnetic (iron oxide particles) contrast media].
Castoldi MC; Fauda V; Scaramuzza D; Vergnaghi D
Radiol Med; 2000 Sep; 100(3):160-7. PubMed ID: 11148882
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
